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Predisposition to retinoblastoma is transmitted as an 
autosomal dominant trait; it is caused by mutations 
in the RB1 gene; penetrance and expressivity 
depend on the nature of the predisposing mutational 
change; there is also a non-hereditary form of 
retinoblastoma (mostly in children with isolated 
unilateral retinoblastoma) that is caused by RB1-
mutations confined to somatic cells. 
Clinics 
Phenotype and clinics 
Retinoblastoma in early childhood: white reflexes 
in one or both eyes or strabismus usually are the 
first signs indicating this malignant eye tumour; in 
most children with the hereditary retinoblastoma, 
both eyes are affected by multiple tumour foci 
(bilateral multifocal retinoblastoma). 
Adults (most often relatives of patients with 
retinoblastoma) may show retinal scars indicating 
regressed retinoblastomas or retinomas (non-
progressive tumours). 
In addition to retinoblastoma, children with 
cytogenetic deletions involving 13q14 may show 
developmental delay and dysmorphic signs. 
Neoplastic risk 
Early childhood: formation of retinoblastomas (see 
genotype-phenotype correlation). 
Adolescence and adulthood: tumours outside the 
eye (second primary neoplasms):  
- osteosarcoma,  
- melanoma,  
- brain tumours (pinealoma in particular some 
patients also show multiple benign tumours of 
adipose tissue (lipoma). 
Treatment 
Retinoblastomas can be cured by (depending on 
size and location): local therapy (photocoagulation, 
cryotherapy, radiation), combined systemic and 
local therapy, or enucleation of the eye; 
surveillance: following the diagnosis of 
retinoblastoma, repeated examinations under 
general anesthesia are required for early diagnosis 
of new tumour foci; up to now, no screening for 
second primary neoplasms. 
Prognosis 
Most often, treatment of retinoblastoma is very 
effective and, therefore, death from retinoblastoma 
is rare; however, life span in patients that develop 
second primary neoplasms is reduced (cumulative 
mortality at age 40: 6.4% in bilateral patients 
without radiotherapy, 1.5% in patients with 
unilateral retinoblastoma). 
Genes involved and 
proteins 





c-RB1 at 13q14 in normal cells: PAC 825K21 - Courtesy 
Mariano Rocchi.  
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Description: 180 kb genomic DNA containing 27 
exons. 
Transcription: 4.7 kb mRNA with 2.7 kb open 
reading frame. 
Protein 
Description: 928 aa nuclear phosphoprotein. 
Localisation: Nucleus. 
Function: Involved in cell cycle regulation. 
Mutations 
Note: Mutations predisposing to retinoblastoma are 
one allele mutations; in retinoblastoma, both copies 
of the RB1 gene are mutated (two-step inactivation 
mechanism typical of tumor suppressor genes). 
Nature and localization of individual mutations are 
heterogeneous regarding their nature: 20% deletions 
larger 1kb; 30% small deletions or insertions; 45% 
point mutations. 
And location: mutations have been found in 25 of 
the 27 coding exons and in promoter elements. 
Genotype-phenotype correlation: most mutant RB1-
alleles show premature termination codons; 
typically, these mutant alleles are associated with 
almost complete penetrance (>95%) and high 
expressivity (more than 6 individual retinoblastoma 
foci per individual and, therefore, most often 
involvement of both eyes); some rare mutant alleles 
that code for proteins with retention of parts of the 
functions of the wild-type prote in or that result in 
diminished amounts of wild-type transcript are 
associated with incomplete penetrance (<75%) and 
low expressivity (mean of less than 2 tumor foci). 
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